Comments
Loading...

Y-mAbs Therapeutics Analyst Ratings

YMABNASDAQ
Logo brought to you by Benzinga Data
$4.80
0.000.00%
Pre-Market: 4:24 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$26.00
Lowest Price Target1
$7.00
Consensus Price Target1
$18.07

Y-mAbs Therapeutics Analyst Ratings and Price Targets | NASDAQ:YMAB | Benzinga

Y-mAbs Therapeutics Inc has a consensus price target of $18.07 based on the ratings of 16 analysts. The high is $26 issued by Canaccord Genuity on August 13, 2024. The low is $7 issued by Morgan Stanley on March 5, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B of A Securities, and Truist Securities on March 21, 2025, March 5, 2025, and March 5, 2025, respectively. With an average price target of $14 between HC Wainwright & Co., B of A Securities, and Truist Securities, there's an implied 191.67% upside for Y-mAbs Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Nov 24
2
Dec 24
1
Jan
2
1
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
B of A Securities
Truist Securities
Morgan Stanley
Brookline Capital

1calculated from analyst ratings

Analyst Ratings for Y-mAbs Therapeutics

Buy NowGet Alert
03/21/2025Buy Now150%HC Wainwright & Co.
Robert Burns41%
$22 → $12MaintainsBuyGet Alert
03/05/2025Buy Now150%B of A Securities
Alec Stranahan33%
$14 → $12MaintainsNeutralGet Alert
03/05/2025Buy Now275%Truist Securities
Nicole Germino48%
$21 → $18MaintainsBuyGet Alert
03/05/2025Buy Now45.83%Morgan Stanley
Michael Ulz60%
$11 → $7MaintainsUnderweightGet Alert
01/13/2025Buy Now358.33%HC Wainwright & Co.
Robert Burns41%
$22 → $22ReiteratesBuy → BuyGet Alert
12/11/2024Buy Now—HC Wainwright & Co.
Robert Burns41%
—ReiteratesBuy → BuyGet Alert
12/05/2024Buy Now254.17%Brookline Capital
Kemp Dolliver32%
→ $17Initiates → BuyGet Alert
11/18/2024Buy Now379.17%Oppenheimer
Jeff Jones32%
→ $23Initiates → OutperformGet Alert
11/15/2024Buy Now358.33%HC Wainwright & Co.
Robert Burns41%
$22 → $22ReiteratesBuy → BuyGet Alert
09/10/2024Buy Now379.17%Wedbush
David Nierengarten61%
$23 → $23ReiteratesOutperform → OutperformGet Alert
09/09/2024Buy Now316.67%Cantor Fitzgerald
Li Watsek40%
$20 → $20ReiteratesOverweight → OverweightGet Alert
08/16/2024Buy Now316.67%Cantor Fitzgerald
Li Watsek40%
→ $20Initiates → OverweightGet Alert
08/13/2024Buy Now441.67%Canaccord Genuity
Bill Maughan19%
$26 → $26MaintainsBuyGet Alert
08/13/2024Buy Now129.17%Morgan Stanley
Michael Ulz60%
$12 → $11MaintainsUnderweightGet Alert
08/13/2024Buy Now358.33%HC Wainwright & Co.
Robert Burns41%
$22 → $22ReiteratesBuy → BuyGet Alert
08/13/2024Buy Now420.83%BMO Capital
Etzer Darout45%
$26 → $25MaintainsOutperformGet Alert
07/11/2024Buy Now379.17%Jones Trading
Justin Walsh40%
→ $23Initiates → BuyGet Alert
06/28/2024Buy Now337.5%Truist Securities
Nicole Germino48%
→ $21Initiates → BuyGet Alert
05/13/2024Buy Now358.33%HC Wainwright & Co.
Robert Burns41%
$21 → $22MaintainsBuyGet Alert
03/06/2024Buy Now358.33%HC Wainwright & Co.
Robert Burns41%
$21 → $22MaintainsBuyGet Alert
03/04/2024Buy Now441.67%Canaccord Genuity
Bill Maughan19%
$22 → $26MaintainsBuyGet Alert
03/04/2024Buy Now441.67%BMO Capital
Etzer Darout45%
$16 → $26MaintainsOutperformGet Alert
02/20/2024Buy Now337.5%HC Wainwright & Co.
Robert Burns41%
$11 → $21MaintainsBuyGet Alert
11/15/2023Buy Now129.17%HC Wainwright & Co.
Robert Burns41%
→ $11ReiteratesBuy → BuyGet Alert
08/22/2023Buy Now45.83%JP Morgan
Tessa Romero61%
$8 → $7MaintainsUnderweightGet Alert
08/14/2023Buy Now4.17%Morgan Stanley
Michael Ulz60%
$7 → $5MaintainsUnderweightGet Alert
08/14/2023Buy Now129.17%HC Wainwright & Co.
Robert Burns41%
→ $11ReiteratesBuy → BuyGet Alert
07/25/2023Buy Now358.33%Canaccord Genuity
William Plovanic56%
$21 → $22MaintainsBuyGet Alert
06/07/2023Buy Now337.5%Canaccord Genuity
William Plovanic56%
→ $21ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now150%B of A Securities
Alec Stranahan33%
$6 → $12MaintainsNeutralGet Alert
05/10/2023Buy Now45.83%Morgan Stanley
Michael Ulz60%
$4 → $7MaintainsUnderweightGet Alert
05/10/2023Buy Now170.83%Wedbush
David Nierengarten61%
$5 → $13UpgradeNeutral → OutperformGet Alert
05/09/2023Buy Now337.5%Canaccord Genuity
William Plovanic56%
$18 → $21MaintainsBuyGet Alert
04/04/2023Buy Now129.17%HC Wainwright & Co.
Robert Burns41%
$19 → $11MaintainsBuyGet Alert
04/03/2023Buy Now—Guggenheim
Etzer Darout45%
—DowngradeBuy → NeutralGet Alert
04/01/2023Buy Now25%B of A Securities
Alec Stranahan33%
→ $6MaintainsNeutralGet Alert
03/31/2023Buy Now275%Canaccord Genuity
William Maughan71%
$20 → $18MaintainsBuyGet Alert
01/30/2023Buy Now170.83%BMO Capital
Etzer Darout45%
$12 → $13MaintainsOutperformGet Alert
01/27/2023Buy Now—Morgan Stanley
Michael Ulz60%
—DowngradeEqual-Weight → UnderweightGet Alert
01/05/2023Buy Now—Cowen & Co.
Joseph Thome34%
—DowngradeOutperform → Market PerformGet Alert
12/15/2022Buy Now25%B of A Securities
Alec Stranahan33%
$5 → $6MaintainsNeutralGet Alert
12/02/2022Buy Now4.17%B of A Securities
Alec Stranahan33%
$23 → $5DowngradeBuy → NeutralGet Alert
11/01/2022Buy Now150%BMO Capital
Etzer Darout45%
$29 → $12MaintainsOutperformGet Alert
10/31/2022Buy Now462.5%Canaccord Genuity
William Maughan71%
$35 → $27MaintainsBuyGet Alert
10/31/2022Buy Now66.67%Morgan Stanley
Michael Ulz60%
$17 → $8MaintainsEqual-WeightGet Alert
10/31/2022Buy Now25%Wedbush
David Nierengarten61%
→ $6DowngradeOutperform → NeutralGet Alert
10/31/2022Buy Now295.83%HC Wainwright & Co.
Robert Burns41%
$63 → $19MaintainsBuyGet Alert
10/31/2022Buy Now45.83%JP Morgan
Tessa Romero61%
$16 → $7DowngradeNeutral → UnderweightGet Alert
09/09/2022Buy Now254.17%Morgan Stanley
Michael Ulz60%
$15 → $17MaintainsEqual-WeightGet Alert
06/24/2022Buy Now462.5%BMO Capital
Etzer Darout45%
→ $27Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Y-mAbs Therapeutics (YMAB) stock?

A

The latest price target for Y-mAbs Therapeutics (NASDAQ:YMAB) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $12.00 expecting YMAB to rise to within 12 months (a possible 150.00% upside). 19 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Y-mAbs Therapeutics (YMAB)?

A

The latest analyst rating for Y-mAbs Therapeutics (NASDAQ:YMAB) was provided by HC Wainwright & Co., and Y-mAbs Therapeutics maintained their buy rating.

Q

When was the last upgrade for Y-mAbs Therapeutics (YMAB)?

A

The last upgrade for Y-mAbs Therapeutics Inc happened on May 10, 2023 when Wedbush raised their price target to $13. Wedbush previously had a neutral for Y-mAbs Therapeutics Inc.

Q

When was the last downgrade for Y-mAbs Therapeutics (YMAB)?

A

The last downgrade for Y-mAbs Therapeutics Inc happened on April 3, 2023 when Guggenheim changed their price target from N/A to N/A for Y-mAbs Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Y-mAbs Therapeutics (YMAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.

Q

Is the Analyst Rating Y-mAbs Therapeutics (YMAB) correct?

A

While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a maintained with a price target of $22.00 to $12.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $4.80, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch